On Feb. 24, 2020, Seqirus announced that the U.S. Food and Drug Administration (FDA) had approved the first adjuvanted quadrivalent influenza vaccine, FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted), to help protect adults 65 years and older against seasonal influenza.

In the U.S., influenza impacts adults 65 years and older with higher hospitalization and death rates compared to young, healthy adults. During the 2017/18 influenza season, 70 percent of influenza-related hospitalizations and 90 percent of influenza-related deaths occurred in this age group. Influenza vaccine effectiveness also tends to be lower in this population due to age-related immune decline, which reduces the body’s ability to produce a sufficient, protective immune response to the vaccine.

FLUAD QUADRIVALENT (aQIV) utilizes the same MF59® adjuvant technology as FLUAD® (aTIV), designed to create a strong, broad and durable immune response. FLUAD QUADRIVALENT includes an additional strain to FLUAD, which has an extensive clinical legacy, with 114+ million doses distributed and licensure in 29 countries since it was first approved in 1997